Latest Headlines

  1. Terray Announces EMMI, An AI-Native Drug Discovery Platform For de Novo Small Molecule Drug Discovery 11/17/2025

    Terray Therapeutics, an AI-native, chemistry-first, biotech today announced its AI and experimental platform, EMMI, and the introduction of advanced Select models that choose the most impactful molecules to make and test in every cycle of drug discovery.

  2. EMA Positive Opinion For Orphan Drug Designation To BioInvent's BI 1808 For The Treatment Of Cutaneous T-cell Lymphoma 11/17/2025

    BioInvent International AB (“BioInvent”), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has adopted a positive opinion for Orphan Drug Designation (ODD) to the company’s investigational medicinal product BI-1808, a first-in-class anti-TNFR2 antibody, for the treatment of Cutaneous T-cell Lymphoma (CTCL).

  3. Silo Pharma Partners With Allucent To Support Planned FDA Investigational New Drug Application For SPC-15 As A Therapeutic For PTSD 11/17/2025

    Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that it has selected Allucent, a global full-service clinical research organization (CRO), to support the Company’s final preparations and planned submission of its investigational new drug application (IND) to the FDA for a Phase 1 clinical trial of its intranasal prophylactic SPC-15 as a treatment for PTSD.

  4. Celcuity Announces Completion Of Submission Of Its New Drug Application To The U.S. FDA For Gedatolisib In HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer 11/17/2025

    Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion of the submission of its New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for gedatolisib in hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), advanced breast cancer (“ABC”).

  5. BullFrog AI To Present bfPREP At The AI Drug Discovery & Development Summit 2025 11/12/2025

    BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that it will present a technical talk at the upcoming AI Drug Discovery & Development Summit 2025, taking place November 18–20, 2025, in Boston, Massachusetts.

  6. BenchSci And Mila Partner To Advance AI For Biological Inference And Accelerate Drug Discovery 11/12/2025

    BenchSci, a leading provider of AI software for biopharma research and development, and Mila - Quebec Artificial Intelligence Institute, one of the world’s premier AI research centers, today announced a multi-year partnership to advance the use of artificial intelligence for biological inference.

  7. BostonGene And Kyoto University Partner To Accelerate Precision Drug Development 11/12/2025

    BostonGene, developer of the leading AI foundation model for cancer and the immune system, and Kyoto University, a research institution known for its groundbreaking advancements in medicine and science announced today a research collaboration to develop advanced biological signatures to enhance targeted treatment strategies for patients with esophageal squamous cell carcinoma (ESCC).

  8. Avenzo Therapeutics Granted Fast Track Designation For AVZO-1418, A Potential Best-In-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, For The Treatment Of Patients With EGFR-Mutated TKI-Pretreated NSCLC 11/10/2025

    Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the U.S. Food and Drug Administration (FDA) granted Fast Track designation to AVZO-1418 (DB-1418), a potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate (BsADC).

  9. Why Creative Biolabs Is Betting On AI-Driven Chemical Synthesis To Accelerate Drug Innovation 11/10/2025

    Within the research and development (R&D) sphere, Creative Biolabs serves its clients across all the important areas of pharmaceutical development—right from molecular design to the complex drug substance preparation.

  10. Insilico And Lilly Enter A Research & Licensing Collaboration To Advance AI-Driven Drug Discovery 11/10/2025

    Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced a research collaboration with Eli Lilly ("Lilly") that the two parties will combine Insilico's state-of-the-art Pharma.AI platforms with Lilly's development and disease expertise to jointly discover and advance innovative therapies.